Sir,
Gregor et al. [1] recently demonstrated the presence of certain antibodies directed towards monomeric, unmodified human serum albumin in diabetes. These antibodies were of the IgM class and occurred with a five-fold higher frequency in sera from diabetic patients (5.2%) than in sera from nondiabetic persons (0.% 1.6%). The authors show that these antibodies are different from the antibodies directed specifically towards polymerized albumin. The latter were described by a group of Romanian authors in patients with hepatitis or otherwise affected liver [2] .
I should like to complete these data, the study of polymerized antialbumin antibodies having extended to certain groups of diabetic patients as well [3] . However, the titres were convincingly modified only in the diabetic patients with concomitant affection of the liver or at least a past history of viral hepatitis.
With reference to the specificity of these antibodies, the question arises whether a net delineation may be established between antibodies towards monomeric albumin specific of diabetes (representing a viral etiology marker) and antibodies towards polymerized albumin specific of liver disease. It is not clear in the paper by Gregor et al. [1] if the nine diabetic patients, positive for IgM albumin antibodies, had a past history of hepatitis; it is mentioned that only two of these subjects were found seropositive for hepatitis B surface/core antigens. Separation between the two kinds of anti-albumin antibodies may not be so categorical, at least from the viewpoint of their formation. Reply from the authors Sir, Dr. Cheta raises the question whether a net delineation may be established between the specificity of antibodies directed towards monomeric albumin occuring with an increased frequency in diabetes and the specificity of antibodies directed towards polymerized albumin occuring in liver disease. Consideration of all available data conclusively indicates the existence of two classes of albumin antibodies which differ with regard to their specificities. In our study, only 2 of the 9 diabetic patients who carried IgM albumin antibodies had a history of liver affection as judged from both serology and anamnesis. Antibodies against monomeric albumin were not demonstrable in sera from 50 patients not known to be diabetic but suffering from a broad spectrum of liver affections (hepatitis A acute; acute hepatitis B; non AB; chronic progressive B; chronic persistent B, medication induced; or cirrhosis) (unpublished observation). Cheta et al. [1] found increased titres of antibodies against polymerized albumin only in diabetic patients with hepatic involvement.
In patients with liver affections, the antigenic determinant seems therefore to involve features of the crosslink between the albumin molecules which are not present in monomeric albumin. The antibodies directed against monomefic albumin also react with polymerized albumin, as it contains the antigenic determinant of monomeric albumin. It would be of interest to know whether the sera from the diabetic patients showing reactivity against polymefized albumin are also positive towards monomeric albumin (not included in the data of Cheta et al.) Such information would allow a differentiation between reactivity towards polymerized albumin (as a marker for liver affections) and reactivity towards monomefic albumin (found in diabetes) reacting with polymerized albumin as well.
It is likely, although unproven, that the mechanism of formation of the two kinds of anti-albumin antibodies is similar. In both instances alterations in structure are implied which render endogenous albumin antigenic. These alterations arise from crosslinking of albumin in liver affections and from an alleged binding of albumin to a B cell tropic virus in Type 1 (insulin-dependent) diabetes.
Yours sincerely, I. Gregor and R. Fltickiger
